Figure 9.

SFRE synergised with pembrolizumab in the inhibition of NSCLC cell proliferation. H1299 and H1975 NSCLC cells were treated concomitantly with SFRE at a fixed dose of 1/2xIC₅₀ and with pembrolizumab at the indicated doses. (A) The combinatory index (CI) according to Chou–Talay method indicated a positive synergism between SFRE and pembrolizumab in the inhibition of NSCLC proliferation. (B) FACs analysis of the expression of PD-L1 after 3h and 24h SFRE treatment of NSCLC cells at two different doses (1/2xIC₅₀, and 1xIC₅₀. (C) FACS analysis of the double expression of PD-L1 and CXCR1 after 3h and 24h SFRE treatment of NSCLC cells at two different doses (1/2 IC50, and 1xIC50. Data are expressed as fold induction respect to the expression levels of non-treated cells. Results are expressed as the mean ± SEM of three independent experiments, each performed in triplicates. Asterisks * indicates p-values < 0.05.